PKTX Stock Overview
A research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ProtoKinetix, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0095 |
| 52 Week High | US$0.029 |
| 52 Week Low | US$0.008 |
| Beta | 0.00038 |
| 11 Month Change | -12.50% |
| 3 Month Change | -14.86% |
| 1 Year Change | -47.50% |
| 33 Year Change | -89.84% |
| 5 Year Change | -90.31% |
| Change since IPO | 136.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| PKTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | 2.4% | 2.2% |
| 1Y | -47.5% | 16.2% | 31.7% |
Return vs Industry: PKTX underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: PKTX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| PKTX volatility | |
|---|---|
| PKTX Average Weekly Movement | 35.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PKTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PKTX's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Clarence Smith | www.protokinetix.com |
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions, including ophthalmology, dermatology, transplants, and biomanufacturing. It has a collaboration research agreement with the University of British Columbia.
ProtoKinetix, Incorporated Fundamentals Summary
| PKTX fundamental statistics | |
|---|---|
| Market cap | US$3.47m |
| Earnings (TTM) | -US$374.15k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.3x
P/E RatioIs PKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PKTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$374.15k |
| Earnings | -US$374.15k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.001 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PKTX perform over the long term?
See historical performance and comparison